Navigation Links
Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease

Physician Familiarity and its Better Side-Effect/Safety Profile are Driving

Aricept Prescription Rates, According to a New Report from Decision


WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eisai/Pfizer's Aricept owns a dominating 42.4% patient share for first-line treatment of newly diagnosed Alzheimer's disease patients. The new report entitled Treatment Algorithms in Alzheimer's Disease finds that the reasons for favoring Aricept differ between primary care physicians and neurologists. Primary care physicians prefer Aricept over other acetylcholinesterase inhibitors (AChEIs) largely because of their familiarity with the agent, while neurologists cite Aricept's side-effect/safety profile and easier titration (the dosing schedule needed for a patient to receive full therapeutic doses of a drug).

The report finds that, in first-line treatment, Aricept holds a 42.4% patient share. The two twice-per-day AChEIs -- Novartis's Exelon and Shire/Janssen/Ortho-McNeil's Razadyne hold only 2.8% and 1.4% shares, respectively. Aricept's first-line patient share also far exceeds that of the newer formulations of those two drugs, including the once-daily formulation of Razadyne, Razadyne ER.

"Aricept's critical attribute of once-daily administration was unique until the launch of Razadyne ER in 2005," said Madhuri Borde, Ph.D., analyst at Decision Resources. "However, our survey revealed that physicians prescribe Aricept more than any other AChEI, in large part because of their comfort level with the drug, and because primary care physicians have been slow to move to Razadyne ER."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides the following:

-- Qualitative diagnosis and referral patterns for the United States

based on thought leader input and guideline recommendations.

-- Quantitative treatment algorithms based on patient-level claims data

Product share (class and specific compound level) within each line

of therapy (1st, 2nd, 3rd line).

-- Practicing physician opinion on why specific drugs are chosen for

certain patient populations.

-- Discussion of key drug combinations (including add versus switch

patterns) by lines of therapy.

-- Progression of therapy from key 1st line products (e.g., initial

treatment with Lipitor to 2nd line, 3rd line; initial treatment with

Zocor to 2nd line, 3rd line).

-- Pathway to key therapies from previous therapies (e.g., how much

Avandamet use is preceded by metformin, Avandia, or both as single


-- Qualitative analysis of 2-year forecast incorporating practicing

physician sentiment towards upcoming launches, changes in

reimbursement, etc.

About Decision Resources

Decision Resources, Inc., ( is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
5. Breakthrough Opportunity for Improving Patient Health
6. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Difficult to Treat Erectile Dysfunction Patients
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... -- On Wednesday, June 22, 2016, the NASDAQ ... Dow Jones Industrial Average edged 0.27% lower to finish at ... has initiated coverage on the following equities: Infinity Pharmaceuticals ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... Learn more about these stocks by accessing their free trade ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
(Date:6/22/2016)... SAN DIEGO , June 22, 2016 /PRNewswire/ ... partnership that will allow them to produce up ... (HiPSC) from one lot within one week. These ... their time laboriously preparing cells and spend more ... made possible through a proprietary, high-volume manufacturing process ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
Breaking Biology News(10 mins):